Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
TG2101V01
Phase 3 mab active
Quick answer
Recombinant SARS-CoV-2 fusion protein vaccine (V-01) for COVID-19 Pandemic is a Phase 3 program (mab) at Livzon Pharmaceutical Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Livzon Pharmaceutical Group
- Indication
- COVID-19 Pandemic
- Phase
- Phase 3
- Modality
- mab
- Status
- active